Summary & Overview
HCPCS C9014: Injection, cerliponase alfa, 1 mg
HCPCS Level II code C9014 designates the injectable biologic cerliponase alfa, billed per 1 mg unit. Cerliponase alfa is an enzyme replacement therapy used in specialized clinical settings; accurate coding ensures appropriate tracking of utilization and supports payer processing for high-cost, specialty pharmaceuticals. Nationally, clarity around HCPCS Level II drug codes matters for pharmacy distribution, hospital outpatient billing, and Medicare and commercial payer coverage determinations.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication outlines benchmark considerations for unit-based billing of high-cost biologics, summarizes common modifier usage where available, and highlights policy and coverage themes that affect reimbursement and prior authorization practices.
The report is intended for revenue cycle leaders, hospital pharmacy managers, and specialty pharmacy stakeholders seeking a national-level reference on coding and billing considerations for cerliponase alfa. Data not available in the input will be identified explicitly in relevant sections of the full publication.
Billing Code Overview
HCPCS Level II code C9014 describes Injection, cerliponase alfa, 1 mg. This code represents the administration of a recombinant enzyme replacement therapy formulated as an injectable medication. The service type is a drug administration/injectable biological product. The typical site of service for this therapy is an outpatient infusion center or hospital outpatient department, where specialized administration and monitoring can occur.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric patient with a confirmed diagnosis of CLN2 disease (neuronal ceroid lipofuscinosis type 2) presents for administration of enzyme replacement therapy with C9014 (injection, cerliponase alfa, 1 mg). Typical workflow: the patient arrives at an outpatient pediatric infusion center or hospital outpatient department accompanied by caregivers. A multidisciplinary team including a pediatric neurologist, infusion nurse, and pharmacy prepares the dose based on weight and vial sizing. Pre-infusion nursing assessment includes vital signs, review of recent seizure activity, airway assessment, and allergies. Premedication (antihistamine and/or corticosteroid) may be given per institutional protocol to reduce infusion-related reactions. The infusion is administered via intravenous line over the recommended time with continuous monitoring for hypersensitivity, fever, or respiratory symptoms. Post-infusion observation occurs for a specified period; discharge instructions include monitoring for delayed reactions and scheduling of the next dosing interval. Documentation includes the HCPCS code C9014, lot number, dose administered in milligrams, infusion start/stop times, any modifiers as applicable, and the supervising provider with taxonomy and signature.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
51 | Multiple procedures |